Early this morning, Legacy Acquisition Corp. (LGC), released the details of their shareholder vote to approve their new extension deadline and 100% of the shares that voted, voted “Yes”. Additionally, only 694,820 shares elected to redeem. That’s pretty good. As a result, an aggregate of $7,108,742.34 (or approximately $10.23 per share) will be removed from the Company’s trust, leaving approximately $299.8 million. Post-vote, approximately 29,305,000 public shares will remain issued and outstanding.
Legacy now has until December 21, 2019, to complete their business combination. However, Legacy can extend for five additional 30-day periods to May 21, 2020. Legacy will make their first cash contribution to the trust account in an amount equal to $0.03 for each public share that was not redeemed, starting approximately November 21st, which was their previous deadline.
You can review the results of the vote HERE, but a summary has also been provided below.
The Extension Amendment:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
| 58,700,121 | 2,547,135 | 107,700 | N/A |
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...